Rapid plaque clearance with anti-amyloid therapy for Alzheimer’s disease: in consideration of donanemab treatment duration from real-world cases
warrants further investigation as a reliable, cost-effective surrogate for PET scans to monitor real-time treatment response and guide the timing of discontinuation.
Authors
- Georges Naasan (ORCID: https://orcid.org/0000-0002-6505-630X)
- Jeongyeon Hwang (ORCID: https://orcid.org/0000-0002-0551-3660)
- Sam Gandy
- Fanny M. Elahi
- Alison Pietras
Institutions
- James J. Peters VA Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Neurocase
- Published
- 2026-09-08
- DOI
- https://doi.org/10.1080/13554794.2026.2730462
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00